Journal article
Ensifentrine vs placebo for chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized clinical trials
Expert review of respiratory medicine
19 Apr 2025
PMID: 40252011
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To evaluate the efficacy and safety of ensifentrine in chronic obstructive pulmonary disease (COPD).
We searched electronic databases and registries until 25 January 2025, for randomized clinical trials (RCTs) comparing ensifentrine vs placebo in patients with COPD. Primary outcomes include forced expiratory volume in one second (FEV₁) area under the curve (AUC), peak FEV₁, and morning trough FEV₁.
Ten RCTs involving 2,589 patients were included. Compared with placebo, ensifentrine improved FEV₁ AUC by 104.24 ml (95% CI, 74.03 to 133.44; moderate certainty) on day 1 and by 90.37 ml (95% CI, 54.94 to 125.81; moderate certainty) at study end. Ensifentrine increased peak FEV₁ by 140.99 ml on day 1 (95% CI, 107.48 to 174.5; moderate certainty) and by 118.98 ml at the final assessment (95% CI, 86.49 to 151.47; moderate certainty). Ensifentrine improved morning trough FEV₁ by 42.15 ml (95% CI, 19.87 to 64.43; high certainty). Dose-response analysis showed a bell-shaped curve for all outcomes. Ensifentrine did not significantly differ from placebo in adverse events or improvements in COPD symptoms and quality of life.
Compared with placebo, ensifentrine improved lung function in COPD. Larger RCTs are needed to integrate this bronchodilator benefit with patient-centered outcomes.
CRD42024571928.
Metrics
4 Record Views
Details
- Title
- Ensifentrine vs placebo for chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized clinical trials
- Creators
- Giulia Carvalhal - Universidade Federal de Campina GrandeGonzalo Alberto Peralta-Jiménez - Health Service of Arica and Parinacota, Arica, ChileMaria Meritxell Roca Mora - International University of Catalonia, Barcelona, SpainLaith Ayasa - Harvard UniversityVivian Barrera - Changi General HospitalKavita Advani - University of ConnecticutAntonio Anzueto - The University of Texas Health Science Center at San AntonioJafar Aljazeeri - Drexel University
- Publication Details
- Expert review of respiratory medicine
- Publisher
- Taylor & Francis
- Number of pages
- 10
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pulmonary, Critical Care, and Sleep (Medicine)
- Web of Science ID
- WOS:001473076500001
- Scopus ID
- 2-s2.0-105003104796
- Other Identifier
- 991022048929804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Respiratory System